FRANKFURT (Reuters) – Bayer (BAYGn.DE) on Tuesday faces its second annual investor reckoning over its handling of a wave of U.S. lawsuits claiming its glyphosate-based weedkillers cause cancer.
FILE PHOTO: The logo of Bayer AG is pictured at the facade of the historic headquarters of the German pharmaceutical and chemical maker in Leverkusen, Germany, April 27, 2020. REUTERS/Wolfgang Rattay
Criticism from investors at this year’s annual shareholders’ meeting – held in a virtual format as gatherings are banned due to the coronavirus – will likely be less scathing than it was in 2019.
Bayer shares have plunged by